Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 6, 2016, Pages 1095-1105

  Ren, Zhiguang ^a,b   Gu, Xiaoke ^c,d   Lu, Bin ^e   Chen, Yaqiong ^b,d   Chen, Guojiang ^b   Feng, Jiannan ^b   Lin, Jizhen ^f   Zhang, Yihua ^d   Peng, Hui ^a,d  

^a Institute of Health and Environmental Medicine   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

^d CHINA PHARMACEUTICAL UNIVERSITY   (China)

^e WENZHOU MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anticancer; Bifendate; Multidrug resistance; Nitric oxide

Indexed keywords

ABC TRANSPORTER; CASPASE 3; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN KINASE B; 3-NITROTYROSINE; ANTINEOPLASTIC AGENT; BIFENDATE; BIPHENYL DERIVATIVE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TYROSINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CARBON NUCLEAR MAGNETIC RESONANCE; CELL VIABILITY; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; INFRARED SPECTROMETRY; MASS SPECTROMETRY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HEK293 CELL LINE; K-562 CELL LINE; METABOLISM; MITOCHONDRION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIPHENYL COMPOUNDS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; K562 CELLS; MITOCHONDRIA; NF-KAPPA B; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TYROSINE;

EID: 84969983717     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12796     Document Type: Article

References (40)

1. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219-34.
2. Pauwels EK, Erba P, Mariani G, et al. Multidrug resistance in cancer: its mechanism and its modulation. Drug News Perspect. 2007; 20: 371-7.
3. Crowley E, McDevitt C, Callaghan R. Generating Inhibitors of P-Glycoprotein: where to, Now? Methods Mol Biol. 2010; 596: 405-32.
4. Jin J, Sun H, Wei H, et al. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis. Invest New Drugs. 2007; 25: 95-105.
5. Kong XW, Zhang YH, Wang T, et al. Synthesis and cytotoxic evaluation of novel dimethyl [1, 1'-Biphenyl]-2, 2'-dicarboxylates bearing 1, 3, 4-Thiadiazole moieties. Chem Biodivers. 2008; 5: 1743-52.
6. Bonavida B, Baritaki S, Huerta-Yepez S, et al. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide. 2008; 19: 152-7.
7. Sullivan R, Graham CH. Chemosensitization of cancer by nitric oxide. Curr Pharm Des. 2008; 14: 1113-23.
8. Hutchens S, Manevich Y, He L, et al. Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug PABA/NO. Invest New Drugs. 2011; 29: 719-29.
9. Ling Y, Ye X, Ji H, et al. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. Bioorg Med Chem. 2010; 18: 3448-56.
10. Ling Y, Ye X, Zhang Z, et al. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity. J Med Chem. 2011; 54: 3251-9.
11. Yang CZ, Luan FJ, Xiong DS, et al. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Zhongguo Yao Li Xue Bao. 1995; 16: 333-7.
12. Xu J, Peng H, Chen Q, et al. Oligomerization domain of the multidrug resistance- associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res. 2007; 67: 4373-81.
13. Yang Y, Chen Q, Zhang JT. Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. J Biol Chem. 2002; 277: 44268-77.
14. Xu J, Liu Y, Yang Y, et al. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem. 2004; 279: 19781-9.
15. Peng H, Dong Z, Qi J, et al. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS ONE. 2009; 4: e5676.
16. Wei Y, Ma Y, Zhao Q, et al. New use for an old drug: inhibiting ABCG2 with Sorafenib. Mol Cancer Ther. 2012; 11: 1693-702.
17. Peng H, Qi J, Dong Z, et al. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS ONE. 2010; 5: e15276.
18. Martelli C, Alderighi D, Coronnello M, et al. N, N-bis (cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors. J Med Chem. 2009; 52: 807-17.
19. Gu X, Ren Z, Tang X, et al. Synthesis and biological evaluation of novel bifendate derivatives bearing 6, 7-dihydro-dibenzo[c, e]azepine scaffold as potent P-glycoprotein inhibitors. Eur J Med Chem. 2012; 51: 137-44.
20. Leon L, Jeannin JF, Bettaieb A. Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. Nitric Oxide. 2008; 19: 77-83.
21. Nazarewicz RR, Zenebe WJ, Parihar A, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res. 2007; 67: 1282-90.
22. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters - present status and challenges. Expert Opin Drug Metab Toxicol. 2008; 4: 205-23.
23. Bonavida B, Baritaki S, Huerta-Yepez S, et al. Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis. In: Bonavida B, editors. Nitric oxide (NO) and cancer. Springer: New York; 2010. pp. 459-77.
24. Riganti C, Miraglia E, Viarisio D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 2005; 65: 516-25.
25. Zou ZH, Lan XB, Qian H, et al. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents. Bioorg Med Chem Lett. 2011; 21: 5934-8.
26. Gogvadze V. Targeting mitochondria in fighting cancer. Curr Pharm Des. 2011; 17: 4034-46.
27. Suetsugu A, Jiang P, Yang M, et al. The use of living cancer cells expressing green fluorescent protein in the nucleus and red fluorescence protein in the cytoplasm for real-time confocal imaging of chromosome and cytoplasmic dynamics during mitosis. Anticancer Res. 2015; 35: 2553-7.
28. Yang M, Jiang P, Hoffman RM. Early reporting of apoptosis by real-time imaging of cancer cells labeled with green fluorescent protein in the nucleus and red fluorescent protein in the cytoplasm. Anticancer Res. 2015; 35: 2539-43.
29. Hoffman RM, Yang M. Subcellular imaging in the live mouse. Nat Protoc. 2006; 1: 775-82.
30. Yamamoto N, Jiang P, Yang M, et al. Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res. 2004; 64: 4251-6.
31. Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updates. 2010; 13: 99-108.
32. Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updates. 2009; 12: 114-26.
33. Kopecka J, Campia I, Jacobs A, et al. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget. 2015; 6: 6776-93.
34. Rothweiler F, Michaelis M, Brauer P, et al. Anticancer effects of the nitric oxide- modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia. 2010; 12: 1023-30.
35. Huang Z, Zhang Y, Zhao L, et al. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid. Org Biomol Chem. 2010; 8: 632-9.
36. Chen L, Zhang Y, Kong X, et al. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid. J Med Chem. 2008; 51: 4834-8.
37. ® histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging. Cell Cycle. 2015; 14: 808-19.
38. Yano S, Zhang Y, Zhao M, et al. Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle. 2014; 13: 3958-63.
39. Yano S, Zhang Y, Miwa S, et al. Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle. 2014; 13: 2110-9.
40. Yano S, Miwa S, Mii S, et al. Invading cancer cells are predominantly in G0/G1 resulting in chemoresistance demonstrated by real-time FUCCI imaging. Cell Cycle. 2014; 13: 953-60.